Weekly Analysts’ Ratings Updates for Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals (NASDAQ: MIST) recently received a number of ratings updates from brokerages and research firms:

• 1/6/2026 – Milestone Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
• 12/29/2025 – Milestone Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Milestone Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/21/2025 – Milestone Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/16/2025 – Milestone Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $4.00 to $8.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Milestone Pharmaceuticals had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Milestone Pharmaceuticals was upgraded by analysts at Cowen Inc from a “hold” rating to a “buy” rating.
• 12/15/2025 – Milestone Pharmaceuticals had its price target raised by analysts at HC Wainwright from $5.00 to $8.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Milestone Pharmaceuticals was upgraded by analysts at TD Cowen from a “hold” rating to a “buy” rating. They now have a $8.00 price target on the stock.
• 12/13/2025 – Milestone Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/1/2025 – Milestone Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Milestone Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/23/2025 – Milestone Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.